Leda Leoncini
Low dose 2-chlorodeoxyadenosine given as a single subcutaneous injection in patients with hairy cell leukemia: a multicentre trial SAKK 32/95
Zenhäusern R, Tobler A, Leoncini L, Kovacsovic T, Bargetzi M, Hess U, Gratwohl A, Meyer-Monard S, Solenthaler M, Rufibach K, von Rohr A, Swiss Group for Clinical Cancer Research (SAKK). Low dose 2-chlorodeoxyadenosine given as a single subcutaneous injection in patients with hairy cell leukemia: a multicentre trial SAKK 32/95. Leukemia & lymphoma 2009; 50:133-6.
01.01.2009Low dose 2-chlorodeoxyadenosine given as a single subcutaneous injection in patients with hairy cell leukemia: a multicentre trial SAKK 32/95
01.01.2009Leukemia & lymphoma 2009; 50:133-6
Zenhäusern Reinhard, Tobler Andreas, Leoncini Leda, Kovacsovic Tibor, Bargetzi Mario J, Hess Urs, Gratwohl Alois, Meyer-Monard Sandrine, Solenthaler Max, Rufibach Kaspar, von Rohr Albert, Swiss Group for Clinical Cancer Research (SAKK)
A phase I-II study to determine the maximum tolerated infusion rate of rituximab with special emphasis on monitoring the effect of rituximab on cardiac function
Siano M, Gallino A, Sessa C, Mora O, Leoncini L, Oberson M, Rodriguez-Abreu D, Zucca E, Negretti L, Lerch E, Ghielmini M. A phase I-II study to determine the maximum tolerated infusion rate of rituximab with special emphasis on monitoring the effect of rituximab on cardiac function. Clinical cancer research : an official journal of the American Association for Cancer Research 2008; 14:7935-9.
01.12.2008A phase I-II study to determine the maximum tolerated infusion rate of rituximab with special emphasis on monitoring the effect of rituximab on cardiac function
01.12.2008Clinical cancer research : an official journal of the American Association for Cancer Research 2008; 14:7935-9
Siano Marco, Gallino Augusto, Sessa Cristiana, Mora Oreste, Leoncini Leda, Oberson Michel, Rodriguez-Abreu Delvys, Zucca Emanuele, Negretti Laura, Lerch Erika, Ghielmini Michele